Aether Industries Limited — Q3 FY26
Aether Industries delivered a strong Q3 FY26 with consolidated revenue of ₹317.1 crore (+44% YoY) and EBITDA of ₹108.3 crore (+75% YoY), driven by robust volume growth in large-...
✓ Verified against BSE filing
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
How does Aether treat talent retention as a core priority?
Asked by Sajel Kapoor, antifracy thinking
Management listed general retention efforts but avoided naming any hard tradeoffs made.
Read the exchange
How does Ather treat talent retention as a core priority and what hard tradeoffs has management consciously made in favor of employee continuity?
We spend a lot of time at the management level focusing on this issue. We have attractive ESOPs, packages, incentives across the company. We are very careful in selection of candidates. Surat is a nice city to live in.
How does Aether's culture show up during scale-up experiment failures?
Asked by Sajel Kapoor, antifracy thinking
Management gave specific examples of leadership involvement and safety culture.
Read the exchange
When scaleup experiments fail, how does Aether's culture show up on the ground? What behaviors signal psychological safety and trust?
We lead from the top. Our promoter family is a mix of techno-commercial excellence. We have about 50 projects going on in R&D today, all directly led by myself. We have a culture of stop work at all levels.
Strategy for CM: acquire new customers or gain pocket share?
Asked by Pikshit Gujarati, Nishad
Management clearly stated both strategies and provided supporting details.
Read the exchange
What will be your strategy, will you acquire new CM customers over time or gain pocket share of existing customers?
The answer is both. We work extremely hard in curating relationships with innovators. We want the next 10 products in their pipeline. We are continuously looking for new customers, exhibiting in about 10 shows worldwide.
Time to convert a customer from CRAMS to CM?
Asked by Pikshit Gujarati, Nishad
Management gave a range and an average, directly answering the question.
Read the exchange
How much time does it take to convert a customer from CRAMS to CM?
It really depends. Examples from 6 months to 6 years. On average, between one to two years.
Future revenue contribution from CRAMS/CM vs LSM?
Asked by Pikshit Gujarati, Nishad
Management provided a clear target percentage split.
Read the exchange
Down the line two-three years, what contribution will be from this segment of total revenue?
What we're targeting is basically 70% of our revenue coming from CRAMS and CM and 30% coming from large scale manufacturing.
Name of the new European customer in material science?
Asked by Manishadani, 361 Capital
Management explicitly declined to name the customer.
Read the exchange
Is the customer name because they are also into material science?
We do not name our customers. It's a customer from Europe in the material science sector. We'll not comment anything further.
Entry barriers and pricing pressure in non-pharma non-agro CM?
Asked by Deng, Tiger Assets
Management provided specific reasons for barriers and lack of pricing pressure.
Read the exchange
How high are entry barriers for global chemical players? What makes customers prefer outsourcing to you rather than backward integrating? How protected from pricing pressure?
In the west it's increasingly impossible to manufacture anymore. Pricing has increased significantly in the west. These companies don't typically shop around once they establish strategic partnerships. There is no pricing pressure.
Contract renewal cycle and pricing mechanism?
Asked by Deng, Tiger Assets
Management gave contract duration and pricing mechanism clearly.
Read the exchange
How often are contracts renewed and are they done at fixed prices or linked to spot or raw material prices?
Contracts are usually for five to ten year minimum, then auto-renewed. Pricings are negotiated every year based on open costing sheet platform.
Clarity on other CM contracts and Converge Polyol status?
Asked by Kumar Somia, Ambit Capital
Management gave qualitative update but no quantitative details on other contracts.
Read the exchange
Could you give some more clarity on how the other contracts are panning out? Where are we on Converge Polyol and how is the base legacy contract business doing?
Converge Polyol is picking up very well. A lot of new customers are sampling and have given small quantity orders. One product had a cyclical trend but will turn up good this quarter.
Key products driving LSM improvement?
Asked by Kumar Somia, Ambit Capital
Management declined to name products on the call.
Read the exchange
What would be the key product that would be driving that?
We have several key products on this but we would not like to discuss the products but we can discuss it offline.
Demand trend in pharma and agro business?
Asked by Kumar Somia, Ambit Capital
Management provided specific volume growth percentages.
Read the exchange
How is the demand trend right now in pharma API intermediates?
Volumes have increased quarter on quarter 10%, year on year 25% for us. We are seeing good demand. Prices have bottomed out.
Sustainable EBITDA margin guidance?
Asked by Kumar Somia, Ambit Capital
Management gave a specific margin range and explained the one-time item.
Read the exchange
Will it be fair to assume sustainable EBITDA margin run rate of roughly 34-35%?
We would like to still be conservative and always be around 29 to 30%, not more than that. There's a one-time FLOP claim that has increased margins.
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Volumes increased 10% QoQ, 25% YoY for LSM | 25% | 44% | Understated vs filing |
| CRAMS EBITDA margin 60-65% | 62.5% | 34% | Overstated vs filing |
| CM EBITDA margin 27-30% | 28.5% | 34% | Understated vs filing |
| LSM EBITDA margin 21-23% | 22% | 34% | Understated vs filing |
| Baker Hughes revenue grew 20% QoQ | 20% | 44% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.